TuHURA reported tumor responses lasting more than 6 months in its first 3 patients, FDA clearance for another study, and broader patents. The early results involve only 3 people, and the filing gives no quarterly financial figures, but the program progress supports a favorable read.
The progress gives TuHURA more chances to test its cancer treatments and protect wider uses for its inventions. The patient results are still early because they involve only 3 people. The filing gives no quarterly sales or profit figures, and some operating funds came through a loan facility.
Follow TuHURA Biosciences, Inc. (HURA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for HURA